Shots:

• The approval is based on P-III INVICTUS study including combined safety results from the P-I study which assessing of Qinlock (150mg- qd) vs PBO in ratio (2:1) in patients with advanced GIST whose previous therapies have included imatinib- sunitinib- and regorafenib to evaluate its safety- tolerability- and efficacy
• The study demonstrated median PFS (6.3 mos. vs 1.0 mos.)- reduced the risk of disease progression or death by 85%- mORR of 9.4%- mOS (15.1 mos. vs 6.6 mos.)- reduced the risk of death by 64%
• Qinlock (ripretinib) is kinase inhibitor targeted to treat adult patients with advanced gastrointestinal stromal tumor (GIST)

Click here to read full press release/ article | Ref: Deciphera | Image: Deciphera